Co-Dergocrine Mesylate en es it fr

Co-Dergocrine Mesylate Brand names, Co-Dergocrine Mesylate Analogs

Co-Dergocrine Mesylate Brand Names Mixture

  • No information avaliable

Co-Dergocrine Mesylate Chemical_Formula

C33H45N5O5

Co-Dergocrine Mesylate RX_link

No information avaliable

Co-Dergocrine Mesylate fda sheet

Co-Dergocrine Mesylate msds (material safety sheet)

Co-Dergocrine Mesylate Synthesis Reference

No information avaliable

Co-Dergocrine Mesylate Molecular Weight

591.741 g/mol

Co-Dergocrine Mesylate Melting Point

No information avaliable

Co-Dergocrine Mesylate H2O Solubility

No information avaliable

Co-Dergocrine Mesylate State

Solid

Co-Dergocrine Mesylate LogP

2.615

Co-Dergocrine Mesylate Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Co-Dergocrine Mesylate Indication

For use as an adjunct therapy for patients with dementia

Co-Dergocrine Mesylate Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Co-Dergocrine Mesylate Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Co-Dergocrine Mesylate side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Co-Dergocrine Mesylate Patient Information

No information avaliable

Co-Dergocrine Mesylate Organisms Affected

Humans and other mammals